Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
for Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Drug: Bevacizumab
Sites in Washington D.C. +327 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04181060·Phase 3·Recruiting·Listed Nov 2019